These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 23871799)

  • 21. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
    Shariat SF; Marberger MJ; Lotan Y; Sanchez-Carbayo M; Zippe C; Lüdecke G; Boman H; Sawczuk I; Friedrich MG; Casella R; Mian C; Eissa S; Akaza H; Serretta V; Huland H; Hedelin H; Raina R; Miyanaga N; Sagalowsky AI; Roehrborn CG; Karakiewicz PI
    J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer.
    Dumache R; David D; Kaycsa A; Minciu R; Negru S; Puiu M
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):163-7. PubMed ID: 21682190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer.
    Eissa S; Shabayek MI; Ismail MF; El-Allawy RM; Hamdy MA
    IUBMB Life; 2010 May; 62(5):394-9. PubMed ID: 20408180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers.
    Kamat AM; Hegarty PK; Gee JR; Clark PE; Svatek RS; Hegarty N; Shariat SF; Xylinas E; Schmitz-Dräger BJ; Lotan Y; Jenkins LC; Droller M; van Rhijn BW; Karakiewicz PI;
    Eur Urol; 2013 Jan; 63(1):4-15. PubMed ID: 23083902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorescence detection of bladder cancer using urine cytology.
    Fu CY; Ng BK; Razul SG; Chin WW; Tan PH; Lau WK; Olivo M
    Int J Oncol; 2007 Sep; 31(3):525-30. PubMed ID: 17671678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neural network analysis of clinicopathological and molecular markers in bladder cancer.
    Qureshi KN; Naguib RN; Hamdy FC; Neal DE; Mellon JK
    J Urol; 2000 Feb; 163(2):630-3. PubMed ID: 10647699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [TNM-oriented therapy planning in bladder cancer].
    Goepel M; Rübben H
    Urologe A; 1991 May; 30(3):151-7. PubMed ID: 1871932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients.
    Picozzi S; Ricci C; Gaeta M; Ratti D; Macchi A; Casellato S; Bozzini G; Carmignani L
    J Urol; 2012 Dec; 188(6):2046-54. PubMed ID: 23083867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
    Filbeck T; Pichlmeier U; Knuechel R; Wieland WF; Roessler W
    J Urol; 2002 Jul; 168(1):67-71. PubMed ID: 12050494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion.
    Esrig D; Freeman JA; Elmajian DA; Stein JP; Chen SC; Groshen S; Simoneau A; Skinner EC; Lieskovsky G; Boyd SD; Cote RJ; Skinner DG
    J Urol; 1996 Sep; 156(3):1071-6. PubMed ID: 8709310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
    Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
    Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential of urinary biomarkers in early bladder cancer diagnosis.
    Lam T; Nabi G
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1105-15. PubMed ID: 18028019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.
    Lotan Y; Elias K; Svatek RS; Bagrodia A; Nuss G; Moran B; Sagalowsky AI
    J Urol; 2009 Jul; 182(1):52-7; discussion 58. PubMed ID: 19450825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer].
    Szarvas T
    Magy Onkol; 2009 Dec; 53(4):385-9. PubMed ID: 20071311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer.
    Witjes JA; Douglass J
    Nat Clin Pract Urol; 2007 Oct; 4(10):542-9. PubMed ID: 17921969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
    Kehinde EO; Al-Mulla F; Kapila K; Anim JT
    Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers in bladder cancer.
    Bryan RT; Zeegers MP; James ND; Wallace DM; Cheng KK
    BJU Int; 2010 Mar; 105(5):608-13. PubMed ID: 19793380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.